A Standard Herbal Formula, CGAC, Attenuates Bone Loss by Normalizing Low-Bone Turnover Stagnation in an Orchiectomy-Induced Mouse Model
Pharmaceuticals · 31.03.2026 · 19 (4) · 555
DOI: 10.3390/ph19040555 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 31.03.2026. Verfasst von Dong-Cheol Baek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Bioscience & Integrative Medicine, Daejeon University, Daejeon 35235, Republic of Korea. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Background/Objectives: Osteoporosis is a progressive systemic skeletal disease, with male osteoporosis emerging as a critical global concern due to high morbidity and mortality from fractures. This study investigated the anti-osteoporotic potential of CGAC—a herbal mixture of Cervus elaphus Linnaeus, Glycine max (L.) Merr., Angelica gigas Nakai, and Cnidium officinale Makino—and its underlying mechanisms in an orchiectomized (ORX) mouse model.
Methods
C57BL/6J mice underwent ORX for 8 weeks, followed by CGAC administration (250 and 500 mg/kg) for an additional 8 weeks. Molecular mechanisms were further validated using MG63 osteoblastic and RAW 264.7 osteoclast assays.
Results
ORX induced severe osteoporotic phenotypes, including significant reductions in bone mineral density (BMD) and trabecular microarchitecture. Notably, at the time point examined, ORX was associated with a suppressed bone remodeling state, reflected by reductions in both TRAP-positive osteoclasts and ALP-positive osteoblasts, together with lower serum BALP, CTX-1, and Gla/Glu-OC ratio. Conversely, CGAC normalized this stagnant state and restored physiological remodeling. This was accompanied by reduced marrow fat accumulation through the AMPK signaling axis, which upregulated Runx2 and downregulated PPAR-γ. In vitro results confirmed that CGAC promoted osteoblast differentiation and mineralization while suppressing RANKL-induced osteoclastogenesis. These actions suggest that CGAC may be involved in regulating Wnt/β-catenin signaling.
Conclusions
Overall, CGAC is a promising therapeutic candidate for male osteoporosis, offering pharmacological benefits particularly relevant to aging populations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Bioscience & Integrative Medicine, Daejeon University, Daejeon 35235, Republic of Korea.
- Department of Korean Rehabilitation Medicine, College of Korean Medicine, Daejeon University, Daejeon 35235, Republic of Korea.
ORCID-Profile: Dong-Cheol Baek, Min-Young Chae, Tae-Wook Woo, Chang-Gue Son, Eun-Jung Lee
Förderung
- National Research Foundation of Korea
Zitieren
APA
Baek, D. C., Chae, M. Y., Woo, T. W., Son, C. G., & Lee, E. J. (2026). A Standard Herbal Formula, CGAC, Attenuates Bone Loss by Normalizing Low-Bone Turnover Stagnation in an Orchiectomy-Induced Mouse Model. Pharmaceuticals, 19(4), 555. https://doi.org/10.3390/ph19040555
Vancouver
Baek DC, Chae MY, Woo TW, Son CG, Lee EJ. A Standard Herbal Formula, CGAC, Attenuates Bone Loss by Normalizing Low-Bone Turnover Stagnation in an Orchiectomy-Induced Mouse Model. Pharmaceuticals. 2026;19(4):555. doi:10.3390/ph19040555
BibTeX
@article{Baek2026,
author = {Baek, Dong-Cheol and Chae, Min-Young and Woo, Tae-Wook and Son, Chang-Gue and Lee, Eun-Jung},
title = {A Standard Herbal Formula, CGAC, Attenuates Bone Loss by Normalizing Low-Bone Turnover Stagnation in an Orchiectomy-Induced Mouse Model},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {4},
pages = {555},
doi = {10.3390/ph19040555}
}
EUVIMED